 Allison Wheeler
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 14 | 2025 | 147 | 4.280 |
Why?
| | Hemophilia B | 8 | 2025 | 66 | 2.050 |
Why?
| | Venous Thromboembolism | 5 | 2024 | 324 | 1.930 |
Why?
| | Menorrhagia | 5 | 2024 | 22 | 1.570 |
Why?
| | Thrombosis | 6 | 2024 | 393 | 1.520 |
Why?
| | Blood Coagulation | 5 | 2023 | 268 | 1.290 |
Why?
| | Factor XI Deficiency | 2 | 2020 | 3 | 1.140 |
Why?
| | von Willebrand Diseases | 6 | 2025 | 28 | 1.110 |
Why?
| | Transfusion Medicine | 2 | 2022 | 16 | 0.860 |
Why?
| | Hemorrhage | 12 | 2025 | 809 | 0.860 |
Why?
| | Platelet Transfusion | 2 | 2024 | 80 | 0.820 |
Why?
| | Cost of Illness | 1 | 2025 | 321 | 0.750 |
Why?
| | Anticoagulants | 2 | 2023 | 722 | 0.680 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2020 | 24 | 0.640 |
Why?
| | Models, Statistical | 1 | 2021 | 681 | 0.500 |
Why?
| | Blood Coagulation Factors | 1 | 2016 | 55 | 0.480 |
Why?
| | von Willebrand Factor | 5 | 2024 | 85 | 0.480 |
Why?
| | Hemorrhagic Disorders | 3 | 2022 | 10 | 0.470 |
Why?
| | Quality of Life | 2 | 2025 | 3185 | 0.460 |
Why?
| | Risk Assessment | 3 | 2024 | 3671 | 0.450 |
Why?
| | Blood Component Removal | 2 | 2025 | 28 | 0.440 |
Why?
| | Humans | 63 | 2025 | 144759 | 0.440 |
Why?
| | Hematology | 2 | 2025 | 21 | 0.430 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 985 | 0.390 |
Why?
| | Pediatrics | 1 | 2021 | 1114 | 0.380 |
Why?
| | Blood Coagulation Disorders, Inherited | 2 | 2025 | 4 | 0.360 |
Why?
| | Female | 32 | 2025 | 78271 | 0.360 |
Why?
| | Clinical Trials as Topic | 5 | 2025 | 1053 | 0.360 |
Why?
| | Prospective Studies | 8 | 2025 | 7990 | 0.340 |
Why?
| | Factor IX | 2 | 2023 | 51 | 0.340 |
Why?
| | Thrombocytopenia | 2 | 2024 | 205 | 0.340 |
Why?
| | Young Adult | 13 | 2025 | 14105 | 0.330 |
Why?
| | Adult | 23 | 2025 | 40449 | 0.330 |
Why?
| | Child | 14 | 2025 | 22633 | 0.330 |
Why?
| | Factor VIII | 3 | 2023 | 104 | 0.330 |
Why?
| | Adolescent | 17 | 2025 | 22428 | 0.320 |
Why?
| | Postpartum Hemorrhage | 2 | 2020 | 28 | 0.310 |
Why?
| | Models, Biological | 1 | 2016 | 1821 | 0.290 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 2 | 2025 | 14 | 0.280 |
Why?
| | Blood Coagulation Tests | 2 | 2020 | 70 | 0.280 |
Why?
| | Male | 26 | 2025 | 72315 | 0.270 |
Why?
| | Societies, Medical | 4 | 2025 | 887 | 0.260 |
Why?
| | Middle Aged | 17 | 2025 | 35875 | 0.250 |
Why?
| | Hemostasis | 3 | 2023 | 102 | 0.230 |
Why?
| | Physicians | 2 | 2025 | 939 | 0.230 |
Why?
| | Factor VIIa | 1 | 2025 | 43 | 0.220 |
Why?
| | United States | 13 | 2025 | 15966 | 0.220 |
Why?
| | Genetic Therapy | 2 | 2025 | 313 | 0.210 |
Why?
| | Hemoglobin C Disease | 1 | 2024 | 1 | 0.210 |
Why?
| | Hemoglobinopathies | 1 | 2024 | 6 | 0.210 |
Why?
| | Hemangioendothelioma | 1 | 2023 | 13 | 0.210 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2023 | 8 | 0.210 |
Why?
| | Hematologic Diseases | 1 | 2024 | 66 | 0.200 |
Why?
| | Vascular Neoplasms | 1 | 2023 | 18 | 0.200 |
Why?
| | Cultural Diversity | 1 | 2025 | 87 | 0.200 |
Why?
| | Hemangioma | 1 | 2023 | 46 | 0.200 |
Why?
| | Congresses as Topic | 1 | 2025 | 221 | 0.200 |
Why?
| | Hospitalization | 3 | 2023 | 2433 | 0.200 |
Why?
| | Hirudins | 1 | 2023 | 51 | 0.200 |
Why?
| | Blood Platelets | 2 | 2024 | 400 | 0.200 |
Why?
| | Authorship | 1 | 2023 | 49 | 0.190 |
Why?
| | Child, Hospitalized | 1 | 2023 | 54 | 0.190 |
Why?
| | Sarcoma, Kaposi | 1 | 2023 | 83 | 0.190 |
Why?
| | Sepsis | 3 | 1999 | 640 | 0.190 |
Why?
| | Physicians, Women | 1 | 2024 | 88 | 0.190 |
Why?
| | Tranexamic Acid | 1 | 2023 | 53 | 0.180 |
Why?
| | Antibodies, Bispecific | 1 | 2023 | 64 | 0.180 |
Why?
| | Awards and Prizes | 1 | 2023 | 70 | 0.180 |
Why?
| | Publishing | 1 | 2023 | 114 | 0.180 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2022 | 133 | 0.180 |
Why?
| | Transfusion Reaction | 1 | 2022 | 63 | 0.180 |
Why?
| | Abortion, Spontaneous | 1 | 2022 | 115 | 0.180 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2022 | 27 | 0.180 |
Why?
| | Probability | 1 | 2022 | 310 | 0.180 |
Why?
| | Cohort Studies | 5 | 2025 | 5960 | 0.180 |
Why?
| | Seasons | 1 | 2024 | 556 | 0.170 |
Why?
| | Pain | 2 | 2025 | 779 | 0.170 |
Why?
| | Computer Systems | 1 | 2021 | 56 | 0.170 |
Why?
| | Contraceptive Agents, Female | 1 | 2022 | 80 | 0.170 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 294 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 488 | 0.170 |
Why?
| | Acute Lung Injury | 1 | 2024 | 303 | 0.160 |
Why?
| | Aged | 8 | 2025 | 25913 | 0.160 |
Why?
| | Immunization, Passive | 2 | 2021 | 87 | 0.160 |
Why?
| | Watchful Waiting | 1 | 2021 | 89 | 0.160 |
Why?
| | Anemia | 1 | 2022 | 188 | 0.160 |
Why?
| | Blood Coagulation Factor Inhibitors | 1 | 2019 | 4 | 0.160 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2021 | 154 | 0.150 |
Why?
| | Diagnostic Errors | 1 | 2020 | 175 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1720 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2025 | 17066 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 730 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 348 | 0.140 |
Why?
| | Costs and Cost Analysis | 1 | 2019 | 219 | 0.140 |
Why?
| | Needs Assessment | 1 | 2021 | 404 | 0.140 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 112 | 0.130 |
Why?
| | Radioisotopes | 1 | 2017 | 33 | 0.130 |
Why?
| | Synovectomy | 1 | 2017 | 8 | 0.130 |
Why?
| | Hemarthrosis | 1 | 2017 | 22 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2018 | 100 | 0.130 |
Why?
| | Synovitis | 1 | 2017 | 33 | 0.130 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2925 | 0.130 |
Why?
| | Safety | 1 | 2019 | 356 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 359 | 0.120 |
Why?
| | Vaccines | 1 | 2022 | 389 | 0.120 |
Why?
| | Partial Thromboplastin Time | 1 | 2016 | 50 | 0.120 |
Why?
| | Factor XI | 1 | 2016 | 11 | 0.120 |
Why?
| | Anesthesia | 1 | 2020 | 258 | 0.120 |
Why?
| | Blood Coagulation Disorders | 1 | 2018 | 189 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2023 | 847 | 0.120 |
Why?
| | Postoperative Hemorrhage | 1 | 2017 | 104 | 0.120 |
Why?
| | Pregnancy | 4 | 2024 | 7190 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 645 | 0.120 |
Why?
| | Craniocerebral Trauma | 1 | 2018 | 176 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 914 | 0.120 |
Why?
| | Scoliosis | 1 | 2018 | 223 | 0.120 |
Why?
| | Pulmonary Medicine | 1 | 1996 | 79 | 0.110 |
Why?
| | Tonsillectomy | 1 | 2017 | 105 | 0.110 |
Why?
| | Electrocardiography | 1 | 2018 | 662 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2016 | 372 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2022 | 1098 | 0.100 |
Why?
| | Antibodies | 1 | 1996 | 401 | 0.100 |
Why?
| | Polyethylene Glycols | 1 | 2019 | 654 | 0.100 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2013 | 12 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2021 | 974 | 0.100 |
Why?
| | Schwann Cells | 1 | 2013 | 33 | 0.100 |
Why?
| | Neuromuscular Blocking Agents | 1 | 1993 | 26 | 0.100 |
Why?
| | Internal Medicine | 1 | 1996 | 280 | 0.100 |
Why?
| | Risk Factors | 3 | 2024 | 10779 | 0.100 |
Why?
| | Clinical Competence | 1 | 2021 | 1244 | 0.090 |
Why?
| | Infant | 3 | 2024 | 10034 | 0.090 |
Why?
| | Analgesia | 1 | 1993 | 105 | 0.090 |
Why?
| | Intensive Care Units | 2 | 2001 | 916 | 0.090 |
Why?
| | Child, Preschool | 3 | 2024 | 11787 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2001 | 1356 | 0.080 |
Why?
| | Recombinant Proteins | 2 | 2025 | 1370 | 0.080 |
Why?
| | Critical Care | 2 | 2000 | 695 | 0.080 |
Why?
| | Spinal Cord | 1 | 2013 | 380 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2018 | 1209 | 0.080 |
Why?
| | Internship and Residency | 1 | 2021 | 1257 | 0.080 |
Why?
| | Bronchial Fistula | 1 | 1989 | 4 | 0.080 |
Why?
| | Hemoptysis | 1 | 1989 | 36 | 0.080 |
Why?
| | Fistula | 1 | 1989 | 48 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2878 | 0.070 |
Why?
| | Stroke | 1 | 2018 | 1256 | 0.070 |
Why?
| | Positive-Pressure Respiration | 1 | 1990 | 112 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 1996 | 1519 | 0.070 |
Why?
| | Aortic Diseases | 1 | 1989 | 124 | 0.070 |
Why?
| | Phenotype | 1 | 2016 | 3162 | 0.070 |
Why?
| | Shock, Septic | 2 | 2000 | 216 | 0.070 |
Why?
| | Blood Transfusion | 2 | 2022 | 405 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2025 | 11679 | 0.060 |
Why?
| | ADAMTS13 Protein | 1 | 2025 | 7 | 0.060 |
Why?
| | Plasma Exchange | 1 | 2025 | 18 | 0.060 |
Why?
| | Single-Domain Antibodies | 1 | 2025 | 15 | 0.060 |
Why?
| | Hemoglobin C | 1 | 2024 | 1 | 0.050 |
Why?
| | Rare Diseases | 1 | 2025 | 113 | 0.050 |
Why?
| | Respiration, Artificial | 3 | 1999 | 708 | 0.050 |
Why?
| | Antithrombins | 1 | 2023 | 70 | 0.050 |
Why?
| | Vincristine | 1 | 2023 | 140 | 0.050 |
Why?
| | Canada | 1 | 2024 | 428 | 0.050 |
Why?
| | Pain Measurement | 1 | 2025 | 552 | 0.050 |
Why?
| | Dependovirus | 1 | 2023 | 79 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 333 | 0.050 |
Why?
| | Levonorgestrel | 1 | 2022 | 35 | 0.040 |
Why?
| | Sirolimus | 1 | 2023 | 281 | 0.040 |
Why?
| | Photosensitizing Agents | 1 | 2022 | 42 | 0.040 |
Why?
| | Minority Groups | 1 | 2024 | 282 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2025 | 302 | 0.040 |
Why?
| | Hemoglobins | 1 | 2024 | 384 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2023 | 337 | 0.040 |
Why?
| | Pain Management | 1 | 2025 | 405 | 0.040 |
Why?
| | Syndrome | 1 | 2022 | 380 | 0.040 |
Why?
| | Hypoproteinemia | 1 | 2000 | 5 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2023 | 601 | 0.040 |
Why?
| | Patient Selection | 1 | 2025 | 719 | 0.040 |
Why?
| | Blood Donors | 1 | 2022 | 143 | 0.040 |
Why?
| | Exome | 1 | 2022 | 227 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2023 | 699 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2019 | 164 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 405 | 0.040 |
Why?
| | Animals | 3 | 2016 | 38058 | 0.040 |
Why?
| | Language | 1 | 2022 | 321 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 151 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2112 | 0.040 |
Why?
| | Nutritional Physiological Phenomena | 1 | 1999 | 55 | 0.040 |
Why?
| | Hematocrit | 1 | 2018 | 108 | 0.040 |
Why?
| | Geography | 1 | 2019 | 203 | 0.030 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 20 | 0.030 |
Why?
| | Multiple Organ Failure | 1 | 1999 | 124 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 1999 | 144 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 672 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 371 | 0.030 |
Why?
| | Biopsy | 1 | 2021 | 1075 | 0.030 |
Why?
| | Free Radical Scavengers | 1 | 1997 | 82 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 779 | 0.030 |
Why?
| | Thiazoles | 1 | 1997 | 135 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2019 | 284 | 0.030 |
Why?
| | Ibuprofen | 1 | 1997 | 84 | 0.030 |
Why?
| | Acetylcysteine | 1 | 1997 | 139 | 0.030 |
Why?
| | Weight Gain | 1 | 2000 | 556 | 0.030 |
Why?
| | Antifibrinolytic Agents | 1 | 2017 | 62 | 0.030 |
Why?
| | Antibody Affinity | 1 | 1996 | 60 | 0.030 |
Why?
| | Antibody Specificity | 1 | 1996 | 181 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1985 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1560 | 0.030 |
Why?
| | Pulmonary Edema | 2 | 2000 | 106 | 0.030 |
Why?
| | Endotoxemia | 1 | 1996 | 87 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3409 | 0.030 |
Why?
| | Spinal Fusion | 1 | 2018 | 260 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2115 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 326 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2017 | 421 | 0.030 |
Why?
| | Ethidium | 1 | 2013 | 6 | 0.030 |
Why?
| | Purinergic P2X Receptor Antagonists | 1 | 2013 | 7 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1489 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2832 | 0.020 |
Why?
| | Tetrazoles | 1 | 2013 | 50 | 0.020 |
Why?
| | Intracellular Space | 1 | 2013 | 66 | 0.020 |
Why?
| | Cause of Death | 2 | 2000 | 471 | 0.020 |
Why?
| | Sciatic Nerve | 1 | 2013 | 59 | 0.020 |
Why?
| | Anti-Anxiety Agents | 1 | 1993 | 45 | 0.020 |
Why?
| | Vaccination | 1 | 2022 | 1423 | 0.020 |
Why?
| | Paralysis | 1 | 1993 | 67 | 0.020 |
Why?
| | Endocytosis | 1 | 2013 | 168 | 0.020 |
Why?
| | Cell Separation | 1 | 2013 | 307 | 0.020 |
Why?
| | Time Factors | 2 | 2021 | 7173 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2013 | 451 | 0.020 |
Why?
| | Child Abuse | 1 | 2018 | 551 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1486 | 0.020 |
Why?
| | Cell Death | 1 | 2013 | 383 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3333 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2947 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2834 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2013 | 498 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1993 | 338 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1098 | 0.020 |
Why?
| | Functional Residual Capacity | 1 | 1990 | 7 | 0.020 |
Why?
| | Pyridines | 1 | 2013 | 605 | 0.020 |
Why?
| | Prosthesis Failure | 1 | 1989 | 127 | 0.020 |
Why?
| | Cytokines | 1 | 1996 | 2061 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1999 | 1907 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1183 | 0.020 |
Why?
| | Radiography | 1 | 1989 | 844 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5868 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 3121 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4154 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5597 | 0.010 |
Why?
| | Analgesics, Opioid | 1 | 1993 | 1143 | 0.010 |
Why?
| | Survival Rate | 2 | 2000 | 2089 | 0.010 |
Why?
| | Chronic Disease | 1 | 1989 | 1813 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 1996 | 6048 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5992 | 0.010 |
Why?
| | Double-Blind Method | 2 | 1997 | 2029 | 0.010 |
Why?
| | Edema | 1 | 2000 | 124 | 0.010 |
Why?
| | Blood Proteins | 1 | 2000 | 249 | 0.010 |
Why?
| | Thiazolidines | 1 | 1997 | 13 | 0.010 |
Why?
| | Pyrrolidonecarboxylic Acid | 1 | 1997 | 7 | 0.010 |
Why?
| | Thromboxanes | 1 | 1997 | 13 | 0.010 |
Why?
| | Bilirubin | 1 | 1997 | 97 | 0.010 |
Why?
| | Acidosis, Lactic | 1 | 1997 | 45 | 0.010 |
Why?
| | Cardiac Output | 1 | 1997 | 179 | 0.010 |
Why?
| | Lung | 1 | 1990 | 4109 | 0.010 |
Why?
| | Epoprostenol | 1 | 1997 | 131 | 0.010 |
Why?
| | Cysteine | 1 | 1997 | 210 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18339 | 0.010 |
Why?
| | Shock | 1 | 1997 | 108 | 0.010 |
Why?
| | Fever | 1 | 1997 | 311 | 0.010 |
Why?
| | Glutathione | 1 | 1997 | 375 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1997 | 636 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1997 | 724 | 0.010 |
Why?
| | Antioxidants | 1 | 1997 | 549 | 0.010 |
Why?
| | Hemodynamics | 1 | 1997 | 1121 | 0.010 |
Why?
| | Prognosis | 1 | 2000 | 4282 | 0.010 |
Why?
|
|
Wheeler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|